

US EPA ARCHIVE DOCUMENT

208647  
RECORD NO.

122804  
SHAUGHNESSEY NO

REVIEW NO.

EEB REVIEW

DATE: IN 12-3-87 OUT 12-30-87

FILE OR REG. NO. 618-OT

PETITION OR EXP. NO. \_\_\_\_\_

DATE OF SUBMISSION 11-17-87

DATE RECEIVED BY HED 12-01-87

RD REQUESTED COMPLETION DATE 2-8-88

EEB ESTIMATED COMPLETION DATE 2-8-88

RD ACTION CODE/TYPE OF REVIEW 181

TYPE PRODUCT(S) Insecticide

DATA ACCESSION NO(S) \_\_\_\_\_

PRODUCT MANAGER, NO. G. LaRocca (15)

PRODUCT NAME(S) Agri-mec (0.15 LB/GAL EC)

COMPANY NAME Merck Sharp & Dohme Research Laboratories

SUBMISSION PURPOSE Registrant response concerning Mysid

Shrimp life cycle studies

SHAUGHNESSEY NO.

CHEMICAL

% A.I.

Abamectin

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

MEMORANDUM

12-30-87

SUBJECT: Registrant Response Concerning Mysid Shrimp Life Cycle Studies, Reg. No: 618-OT Record No: 208647

FROM: Daniel Rieder, Wildlife Biologist  
Ecological Effects Branch  
Hazard Evaluation Division

THRU: Norman J. Cook, Head, Section 2  
Ecological Effects Branch  
Hazard Evaluation Division

THRU: Henry T. Craven, Acting Chief  
Ecological Effects Branch  
Hazard Evaluation Division TS-769C

TO: George LaRocca PM(15)  
Insecticide/Rodenticide Branch  
Registration Division TS-767C

With this letter, attached, Merck is indicating that they are continuing their effort to perform the shrimp life cycle test EEB requested of them in 1986. They experienced culturing problems with the shrimp at the initial laboratory they had contracted. Now they have contracted another laboratory to do the study. They reported two LC50's that were generated while preparing to do the life cycle test.

CONCURRENCES							
SYMBOL	B-769C	TS-769	TS-767C				
SURNAME	Rieder	Vogelbein	Craven				2
DATE	12-30-87	12-31-87	1/12/88				

<u>Test Type</u>	<u>Results</u>	<u>Laboratory</u>
Flow-through 96-hour	LC50=51 ppt	Environmental Science and Engineering
Flow-through 96-hour	LC50=11 ppt <sup>1</sup>	Springborn Life Sciences

These studies were not submitted for evaluation. The EEB recommends that, under FIFRA Section 6(a)(2), any additional information the registrant has pertaining to these studies be submitted for our evaluation.

This status report provided by the registrant will be maintained by EEB in the Branch file for Abamectin.

---

<sup>1</sup> In this study, there was some mortality in one of the four control replicates, therefore, the test is being repeated prior to initiating the chronic life cycle test.